|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
US4740461A
(en)
|
1983-12-27 |
1988-04-26 |
Genetics Institute, Inc. |
Vectors and methods for transformation of eucaryotic cells
|
|
US4959455A
(en)
|
1986-07-14 |
1990-09-25 |
Genetics Institute, Inc. |
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
EP0281604B1
(en)
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
US5011912A
(en)
|
1986-12-19 |
1991-04-30 |
Immunex Corporation |
Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US4965195A
(en)
|
1987-10-26 |
1990-10-23 |
Immunex Corp. |
Interleukin-7
|
|
US4968607A
(en)
|
1987-11-25 |
1990-11-06 |
Immunex Corporation |
Interleukin-1 receptors
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
AU643427B2
(en)
|
1988-10-31 |
1993-11-18 |
Immunex Corporation |
Interleukin-4 receptors
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5683888A
(en)
|
1989-07-22 |
1997-11-04 |
University Of Wales College Of Medicine |
Modified bioluminescent proteins and their use
|
|
US5292658A
(en)
|
1989-12-29 |
1994-03-08 |
University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center |
Cloning and expressions of Renilla luciferase
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
WO1996033735A1
(en)
|
1995-04-27 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
WO1991018982A1
(en)
|
1990-06-05 |
1991-12-12 |
Immunex Corporation |
Type ii interleukin-1 receptors
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
ES2142801T3
(es)
|
1991-03-11 |
2000-05-01 |
Univ Georgia Res Found |
Clonacion y expresion de luciferasa de renilla.
|
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
EP0590076A4
(en)
|
1991-06-14 |
1997-02-12 |
Dnx Corp |
Production of human hemoglobin in transgenic pigs
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
CA2113113A1
(en)
|
1991-07-08 |
1993-01-21 |
Simon W. Kantor |
Thermotropic liquid crystal segmented block copolymer
|
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
EP0759170B1
(en)
|
1993-09-10 |
2008-07-09 |
The Trustees Of Columbia University In The City Of New York |
Uses of green fluorescent protein
|
|
WO1995021191A1
(en)
|
1994-02-04 |
1995-08-10 |
William Ward |
Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
|
|
US5777079A
(en)
|
1994-11-10 |
1998-07-07 |
The Regents Of The University Of California |
Modified green fluorescent proteins
|
|
US5874304A
(en)
|
1996-01-18 |
1999-02-23 |
University Of Florida Research Foundation, Inc. |
Humanized green fluorescent protein genes and methods
|
|
US5804387A
(en)
|
1996-02-01 |
1998-09-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
FACS-optimized mutants of the green fluorescent protein (GFP)
|
|
US5876995A
(en)
|
1996-02-06 |
1999-03-02 |
Bryan; Bruce |
Bioluminescent novelty items
|
|
US5925558A
(en)
|
1996-07-16 |
1999-07-20 |
The Regents Of The University Of California |
Assays for protein kinases using fluorescent protein substrates
|
|
ATE493998T1
(de)
|
1996-08-08 |
2011-01-15 |
Amylin Pharmaceuticals Inc |
Pharmazeutische zusammensetzung mit einem exendin-4-peptid
|
|
US5976796A
(en)
|
1996-10-04 |
1999-11-02 |
Loma Linda University |
Construction and expression of renilla luciferase and green fluorescent protein fusion genes
|
|
US7091183B1
(en)
|
1996-12-03 |
2006-08-15 |
Boston Medical Center Corporation |
Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
|
|
WO1998024464A1
(en)
*
|
1996-12-03 |
1998-06-11 |
Trustees Of Boston University |
Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
|
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
|
IL129767A0
(en)
|
1996-12-12 |
2000-02-29 |
Prolume Ltd |
Apparatus and method for detecting and identifying infectious agents
|
|
DE122007000044I2
(de)
|
1997-01-07 |
2011-05-05 |
Amylin Pharmaceuticals Inc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
|
CA2196496A1
(en)
|
1997-01-31 |
1998-07-31 |
Stephen William Watson Michnick |
Protein fragment complementation assay for the detection of protein-protein interactions
|
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
ES2293688T5
(es)
|
1997-08-08 |
2011-05-04 |
Amylin Pharmaceuticals, Inc. |
Nuevos compuestos análogos de la exendina.
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
ATE383867T1
(de)
|
1997-11-14 |
2008-02-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
|
MXPA00004670A
(es)
|
1997-11-14 |
2003-07-14 |
Amylin Pharmaceuticals Inc |
Compuestos agonistas de exendina novedosos.
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
EP1054594B1
(en)
|
1998-02-13 |
2007-07-04 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and glp-1
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
JP2002507410A
(ja)
|
1998-03-27 |
2002-03-12 |
プロルーム・リミテッド |
ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
EP1119625B1
(en)
|
1998-10-07 |
2005-06-29 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
|
EP1992641A3
(en)
|
1998-12-07 |
2009-07-29 |
Ipsen Pharma |
GLP-1 analogues
|
|
DE69928006T2
(de)
|
1998-12-22 |
2006-07-13 |
Eli Lilly And Co., Indianapolis |
Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
|
|
US6902744B1
(en)
|
1999-01-14 |
2005-06-07 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist formulations and methods of administration thereof
|
|
ES2278589T3
(es)
|
1999-01-14 |
2007-08-16 |
Amylin Pharmaceuticals, Inc. |
Excendinas destinadas a la inhibicion de glucagon.
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6921748B1
(en)
|
1999-03-29 |
2005-07-26 |
Uutech Limited |
Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
|
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
WO2001051078A1
(en)
|
2000-01-10 |
2001-07-19 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
|
|
MXPA02007231A
(es)
|
2000-01-27 |
2002-12-09 |
Lilly Co Eli |
Proceso para solubilizar los compuestos de peptido 1 similares a glucagon.
|
|
AU5675701A
(en)
|
2000-05-16 |
2001-11-26 |
Sanwa Kagaku Kenkyusho Co |
Agents for preventing or ameliorating insulin resistance and/or obesity
|
|
WO2002085923A2
(en)
|
2001-04-19 |
2002-10-31 |
The Scripps Research Institute |
In vivo incorporation of unnatural amino acids
|
|
US20050159379A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
|
JP4566459B2
(ja)
|
2001-06-07 |
2010-10-20 |
株式会社日立製作所 |
表示装置
|
|
AU2002358469A1
(en)
|
2001-12-21 |
2003-07-15 |
7Tm Pharma A/S |
Modified receptors for the discovery of therapeutic ligands
|
|
PL209734B1
(pl)
|
2002-02-20 |
2011-10-31 |
Emisphere Tech Inc |
Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
|
|
JPWO2003097031A1
(ja)
|
2002-05-22 |
2005-09-15 |
株式会社三和化学研究所 |
メチリデンヒドラジド化合物を有効成分とする、肥満の予防又は改善剤
|
|
WO2003103697A2
(en)
|
2002-06-11 |
2003-12-18 |
Cell Therapeutics Scandinavia Ab |
Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
|
|
BR0311843A
(pt)
|
2002-06-15 |
2005-03-15 |
Enteromed Inc |
Métodos para prevenir, inibir, tratar ou reduzir esteatose hepática não- alcoólica em um animal e para prevenir o desenvolvimento e/ou a reversão do processo de nafld em um animal
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
JP2006213598A
(ja)
|
2003-03-19 |
2006-08-17 |
Sanwa Kagaku Kenkyusho Co Ltd |
ピラゾロピリミジン化合物及びその用途
|
|
DK1641823T3
(da)
|
2003-06-12 |
2011-12-12 |
Lilly Co Eli |
GLP-1-analog fusionsproteiner
|
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
NZ579621A
(en)
|
2004-02-11 |
2011-03-31 |
Amylin Pharmaceuticals Inc |
Hybrid polypeptides with selectable properties
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
US7991890B2
(en)
|
2004-09-30 |
2011-08-02 |
Microsoft Corporation |
Game console communication with a device
|
|
AU2005298689A1
(en)
|
2004-10-25 |
2006-05-04 |
Cytos Biotechnology Ag |
Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
|
|
DK1831252T3
(da)
|
2004-12-22 |
2009-10-05 |
Lilly Co Eli |
GLP-1 analog fusionsproteinformuleringer
|
|
US20060275288A1
(en)
|
2005-01-20 |
2006-12-07 |
Grihalde Nelson D |
GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
|
|
KR20070115947A
(ko)
|
2005-02-11 |
2007-12-06 |
아밀린 파마슈티칼스, 인크. |
선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
EP1882044A1
(en)
|
2005-05-11 |
2008-01-30 |
sanofi-aventis |
Use of a gip promoter polymorphism
|
|
US8097584B2
(en)
|
2005-05-25 |
2012-01-17 |
Novo Nordisk A/S |
Stabilized formulations of insulin that comprise ethylenediamine
|
|
CA2622069A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Uutech Limited |
Treatment of diabetes related obesity
|
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
WO2008006113A2
(en)
|
2006-07-07 |
2008-01-10 |
The Texas A & M University System |
Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
|
|
WO2008019143A2
(en)
|
2006-08-04 |
2008-02-14 |
Amylin Pharmaceuticals, Inc |
Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition
|
|
WO2008021560A2
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
US20090098130A1
(en)
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
CA2677932A1
(en)
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
US8598314B2
(en)
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
|
US20090144162A1
(en)
|
2007-11-29 |
2009-06-04 |
Neil Milne |
Transaction Security Method and Apparatus
|
|
GB0814068D0
(en)
|
2008-08-01 |
2008-09-10 |
Univ Ulster |
Active immunisation against GIP
|
|
ES2574835T3
(es)
|
2008-08-07 |
2016-06-22 |
Ipsen Pharma S.A.S. |
Análogos del polipéptido insulinotrópico dependiente de glucosa
|
|
WO2010016936A1
(en)
|
2008-08-07 |
2010-02-11 |
Ipsen Pharma S.A.S. |
Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
|
|
AU2009280021B2
(en)
|
2008-08-07 |
2012-10-04 |
Ipsen Pharma S.A.S. |
Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
|
|
KR20110043687A
(ko)
|
2008-08-07 |
2011-04-27 |
입센 파마 에스.에이.에스 |
포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 절단형 유사체
|
|
WO2010016940A2
(en)
|
2008-08-07 |
2010-02-11 |
Ipsen Pharma S.A.S. |
Analogues of glucose-dependent insulinotropic polypeptide
|
|
WO2011014680A2
(en)
|
2009-07-31 |
2011-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gastric inhibitory peptide variants and their uses
|
|
KR20120123443A
(ko)
|
2010-01-27 |
2012-11-08 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
|
|
KR20130020765A
(ko)
|
2010-02-16 |
2013-02-28 |
메디뮨 엘엘씨 |
Ｈｓａ-관련 조성물 및 사용방법
|
|
US9023986B2
(en)
|
2010-10-25 |
2015-05-05 |
Hoffmann-La Roche Inc. |
Glucose-dependent insulinotropic peptide analogs
|
|
US8507428B2
(en)
|
2010-12-22 |
2013-08-13 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
|
US20130344524A1
(en)
|
2011-03-08 |
2013-12-26 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Analysis method
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
US9453062B2
(en)
|
2011-06-10 |
2016-09-27 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
|
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
|
JP2015533483A
(ja)
|
2012-09-07 |
2015-11-26 |
サノフイ |
メタボリックシンドロームを治療するための融合タンパク質
|
|
US20160185837A1
(en)
|
2013-08-16 |
2016-06-30 |
Medimmune Limited |
Gip and glp-1 receptor dual-agonists for the treatment of diabetes
|
|
US20160297883A1
(en)
|
2013-12-04 |
2016-10-13 |
Innovative Targeting Solutions, Inc. |
G-protein coupled receptor agonists and methods
|
|
EP3079722B1
(en)
|
2013-12-13 |
2021-03-24 |
Novo Nordisk Health Care AG |
Method for thioether conjugation of proteins
|
|
RU2711478C2
(ru)
|
2013-12-17 |
2020-01-17 |
ЭмЭйчЭс КЕА-ИННОВЕЙШН ЭлЭлСи |
Композиции и способы борьбы с накоплением жировой ткани
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
|
KR101825048B1
(ko)
|
2014-12-31 |
2018-02-05 |
주식회사 제넥신 |
GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
|
|
TWI700291B
(zh)
|
2015-06-22 |
2020-08-01 |
美國禮來大藥廠 |
升糖素及glp-1共激動劑化合物
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
UA127495C2
(uk)
|
2015-12-23 |
2023-09-13 |
Амджен Інк. |
Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
|
|
IL313587A
(en)
|
2017-01-17 |
2024-08-01 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
|
|
EA201992502A1
(ru)
|
2017-06-20 |
2020-04-22 |
Эмджен Инк. |
Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
|
|
EP3642238A1
(en)
|
2017-06-21 |
2020-04-29 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
|